Sep 24th 2012 - Edison Investment Research today published a report on Transgene entitled "JX594 Continues To Impress". In summary, the report says:
Interim Phase II data provided further evidence of JX594/TG6006’s potential in hepatocellular carcinoma (HCC). The high response rates and evidence of the specific activity of JX594 on tumour cells in the HEP016 study suggest intravenous administration of JX594 should lead to a survival benefit. If the full data from this trial and three others are positive, a Phase III study with JX594 could start next year. Important news on TG4040 in HCV infections and TG4010 in non-small cell lung cancer (NSCLC) also could offer catalysts for a re-rating of Transgene’s shares.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »